Alnylam Pharmaceuticals

Jump Financial LLC lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 394.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,776 shares of the biopharmaceutical company's stock after buying an additional 23,748 shares during the…

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) is set to release its earnings data before the market opens on Thursday, August 3rd. Analysts expect Alnylam Pharmaceuticals to post earnings of ($1.71) per share for the quarter. Alnylam Pharmaceuticals has set its FY 2023 guidance at EPS.Parties interested in listening to the company's conference call can…

Entia has closed a successful $20m (£16m) Series A financing round with the capital earmarked for the UK commercial rollout and US regulatory approval of the company’s flagship innovation, Liberty – a comprehensive remote patient monitoring solution for people undergoing cancer treatment. Working at the frontiers of remote patient monitoring and predictive analytics, Entia has…

The dynamics of the dementia market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and also the expected launch of emerging therapies during the forecast period of 2023–2032. LAS VEGAS , July 26, 2023 …

Trans Advocates Say Florida Consent Forms Are Inaccurate, Transphobic New Florida Boards of Medicine and Osteopathic Medicine consent forms required for access to gender affirming care are inaccurate, intentionally vague, and have transphobic language, critics say. Meanwhile, in California Republicans push to end a tax on health savings accounts. WUSF Public Media: These Trans Advocates Say…

Cognizant confirms an expansion of its relationship with Gilead Sciences. Gilead is a leading biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases. Under the agreement, Cognizant will manage Gilead's global IT infrastructure, platforms, applications and advanced analytics, and lead initiatives designed to accelerate its digital transformation. The agreement includes renewal and expansion of Cognizant services…

Here are today's Five Things You Need to Know, including a lawsuit against Nike over a sports bra, Berklee College's president isn't returning and competing "tastes" — Eastie vs Ethnic Boston.

© Reuters. Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories Benzinga - Wall Street Journal Telecom Giants AT&T and Verizon Face Investor Skepticism Over Lead-Cable Issue and Debt Load AT&T Inc (NYSE: T) and Verizon Communications Inc (NYSE: VZ) struggled with toxic lead in their…

R oche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease. If things go well, Roche could pay Alnylam up to $2.8 billion in…

According to DelveInsight, the hypertension market in the 7MM is expected to significantly change during the study period 2019–2032. While the hypertension market has generally shown a positive trend, certain factors could potentially contribute to a decline involving low compliance with antihypertensives or poor access to newer medications. LAS VEGAS , July 19,…

Novartis has commercialized an RNA therapy that treats high cholesterol by hitting a target in the liver. By acquiring DTx Pharma, the Swiss pharmaceutical giant is betting the biotech can take its RNA research to more diseases in more parts of the body. Per deal terms announced this week, Novartis will pay $500 million up…

(Bloomberg) -- BridgeBio Pharma Inc. shares surged after the biotech company’s experimental drug cut deaths among patients suffering from a heart condition in a late-stage trial. Most Read from Bloomberg Survival among patients with transthyretin amyloid cardiomyopathy who received BridgeBio’s acoramidis was 81% after 2 1/2 years, compared with 74% among patients who received a…